Ilyang Pharmaceutical Co., Ltd.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd. carries a market capitalization of 141.07B, placing it among publicly traded companies globally. Its enterprise value stands at 231.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd. has 17.92M shares outstanding.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 8.02. The price-to-sales ratio is 0.50, and the price-to-book ratio stands at 0.56.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Ilyang Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 9.29, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 231.63B versus a market cap of 141.07B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd. maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.35, indicating elevated leverage, while an interest coverage ratio of -2.44 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 7.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -2.98, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 3.86, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.23, useful for judging operating efficiency across full business cycles. The company generates approximately 417.51M in revenue per employee across its workforce of 665.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.39 indicates how many times Ilyang Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd. recorded 5.20B in income tax expense. That works out to an effective tax rate of 23.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.56B, leaving 17.29B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Ilyang Pharmaceutical Co., Ltd.'s stock has declined approximately 46.36% over the past 52 weeks. The 50-day moving average sits at 8,071.80, while the 200-day moving average is 10,277.25.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd. generated 277.96B in revenue and converted that into 17.29B in net income, yielding earnings per share of 985.02. EBITDA reached -5.26B, while operating income came in at -13.73B.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd. holds 17.74B in cash and equivalents against 103.67B in total debt, resulting in a net debt position of 90.27B. Total book value stands at 252.31B, with working capital of -19.02B providing operational flexibility.

Ilyang Pharmaceutical Co., Ltd. produced 34.49B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.21B in capital expenditures, free cash flow totaled 23.28B - equivalent to 1,320.79 per share.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd. posted a gross margin of 39.55, reflecting its pricing power and cost economics. The operating margin of -4.94 and net profit margin of 6.22 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Ilyang Pharmaceutical Co., Ltd. paid dividends of 185.06 per share. The dividend payout ratio of 18.71 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 16.78, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 16.04, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ilyang Pharmaceutical Co., Ltd. shareholders.

Ilyang Pharmaceutical Co., Ltd.'s most recent stock split took place on March 4, 2011 with a 478:501 split ratio.

As of June 30, 2026, Ilyang Pharmaceutical Co., Ltd. has an Altman Z-Score of 1.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.